Drug Profile
Balovaptan - Roche
Alternative Names: RG-7314; RO 5028442; RO 5285119Latest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Roche
- Class Antipsychotics; Anxiolytics; Behavioural disorder therapies; Benzodiazepines; Pyridines; Small molecules; Triazoles; Vascular disorder therapies
- Mechanism of Action Vasopressin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Stroke
- Discontinued Pervasive child development disorders; Post-traumatic stress disorders
Most Recent Events
- 15 Feb 2024 Discontinued - Phase-II for Post-traumatic stress disorders in USA (PO) (Roche pipeline, February 2024)
- 05 Oct 2023 Roche completes the phase-II trial in Post-traumatic stress disorders in USA (PO) (NCT05401565)
- 07 Aug 2023 Hoffmann-La Roche withdrew a phase-II trial prior to enrolment in Stroke (In adults, In the elderly) in USA and Spain (IV) due to sponsor's decision (NCT05399550)